vs
Apellis Pharmaceuticals, Inc.（APLS）与Essent Group Ltd.（ESNT）财务数据对比。点击上方公司名可切换其他公司
Essent Group Ltd.的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$312.4M vs $199.9M），Essent Group Ltd.净利率更高（49.6% vs -29.5%，领先79.1%），Essent Group Ltd.同比增速更快（-0.8% vs -5.9%），Essent Group Ltd.自由现金流更多（$848.7M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 2.3%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Essentra PLC是一家面向全球市场的塑料及纤维产品供应商，总部位于英国牛津郡基德灵顿，业务网络覆盖全球多个区域，目前在伦敦证券交易所上市，可面向各行业客户提供多元化的相关产品及配套服务，在所属细分领域拥有较高的市场认可度。
APLS vs ESNT — 直观对比
营收规模更大
ESNT
是对方的1.6倍
$199.9M
营收增速更快
ESNT
高出5.1%
-5.9%
净利率更高
ESNT
高出79.1%
-29.5%
自由现金流更多
ESNT
多$863.0M
$-14.3M
两年增速更快
APLS
近两年复合增速
2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $312.4M |
| 净利润 | $-59.0M | $155.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 59.1% |
| 净利率 | -29.5% | 49.6% |
| 营收同比 | -5.9% | -0.8% |
| 净利润同比 | -62.2% | -7.7% |
| 每股收益（稀释后） | $-0.40 | $1.61 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSESNT
| Q4 25 | $199.9M | $312.4M | ||
| Q3 25 | $458.6M | $311.8M | ||
| Q2 25 | $178.5M | $319.1M | ||
| Q1 25 | $166.8M | $317.6M | ||
| Q4 24 | $212.5M | $315.0M | ||
| Q3 24 | $196.8M | $316.6M | ||
| Q2 24 | $199.7M | $312.9M | ||
| Q1 24 | $172.3M | $298.4M |
净利润APLSESNT
| Q4 25 | $-59.0M | $155.0M | ||
| Q3 25 | $215.7M | $164.2M | ||
| Q2 25 | $-42.2M | $195.3M | ||
| Q1 25 | $-92.2M | $175.4M | ||
| Q4 24 | $-36.4M | $167.9M | ||
| Q3 24 | $-57.4M | $176.2M | ||
| Q2 24 | $-37.7M | $203.6M | ||
| Q1 24 | $-66.4M | $181.7M |
营业利润率APLSESNT
| Q4 25 | -25.6% | 59.1% | ||
| Q3 25 | 48.7% | 63.9% | ||
| Q2 25 | -18.6% | 72.4% | ||
| Q1 25 | -50.0% | 65.2% | ||
| Q4 24 | -12.3% | 61.9% | ||
| Q3 24 | -24.0% | 65.6% | ||
| Q2 24 | -14.7% | 76.4% | ||
| Q1 24 | -36.0% | 71.6% |
净利率APLSESNT
| Q4 25 | -29.5% | 49.6% | ||
| Q3 25 | 47.0% | 52.7% | ||
| Q2 25 | -23.6% | 61.2% | ||
| Q1 25 | -55.3% | 55.2% | ||
| Q4 24 | -17.1% | 53.3% | ||
| Q3 24 | -29.2% | 55.6% | ||
| Q2 24 | -18.9% | 65.1% | ||
| Q1 24 | -38.5% | 60.9% |
每股收益（稀释后）APLSESNT
| Q4 25 | $-0.40 | $1.61 | ||
| Q3 25 | $1.67 | $1.67 | ||
| Q2 25 | $-0.33 | $1.93 | ||
| Q1 25 | $-0.74 | $1.69 | ||
| Q4 24 | $-0.30 | $1.59 | ||
| Q3 24 | $-0.46 | $1.65 | ||
| Q2 24 | $-0.30 | $1.91 | ||
| Q1 24 | $-0.54 | $1.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $5.8B |
| 总资产 | $1.1B | $7.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSESNT
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSESNT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSESNT
| Q4 25 | $370.1M | $5.8B | ||
| Q3 25 | $401.2M | $5.7B | ||
| Q2 25 | $156.3M | $5.7B | ||
| Q1 25 | $164.2M | $5.7B | ||
| Q4 24 | $228.5M | $5.6B | ||
| Q3 24 | $237.1M | $5.6B | ||
| Q2 24 | $264.3M | $5.4B | ||
| Q1 24 | $266.7M | $5.2B |
总资产APLSESNT
| Q4 25 | $1.1B | $7.4B | ||
| Q3 25 | $1.1B | $7.4B | ||
| Q2 25 | $821.4M | $7.2B | ||
| Q1 25 | $807.3M | $7.2B | ||
| Q4 24 | $885.1M | $7.1B | ||
| Q3 24 | $901.9M | $7.1B | ||
| Q2 24 | $904.5M | $6.7B | ||
| Q1 24 | $831.9M | $6.6B |
负债/权益比APLSESNT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $856.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $848.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 271.7% |
| 资本支出强度资本支出/营收 | 0.1% | 2.4% |
| 现金转化率经营现金流/净利润 | — | 5.52× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $1.5B |
8季度趋势，按日历期对齐
经营现金流APLSESNT
| Q4 25 | $-14.2M | $856.1M | ||
| Q3 25 | $108.5M | $215.9M | ||
| Q2 25 | $4.4M | $189.5M | ||
| Q1 25 | $-53.4M | $221.6M | ||
| Q4 24 | $19.4M | $861.5M | ||
| Q3 24 | $34.1M | $229.2M | ||
| Q2 24 | $-8.3M | $188.7M | ||
| Q1 24 | $-133.0M | $216.9M |
自由现金流APLSESNT
| Q4 25 | $-14.3M | $848.7M | ||
| Q3 25 | $108.3M | $210.6M | ||
| Q2 25 | $4.4M | $188.8M | ||
| Q1 25 | $-53.4M | $221.3M | ||
| Q4 24 | $19.3M | $854.8M | ||
| Q3 24 | — | $228.7M | ||
| Q2 24 | $-8.4M | $187.6M | ||
| Q1 24 | $-133.3M | $212.5M |
自由现金流率APLSESNT
| Q4 25 | -7.1% | 271.7% | ||
| Q3 25 | 23.6% | 67.5% | ||
| Q2 25 | 2.5% | 59.2% | ||
| Q1 25 | -32.0% | 69.7% | ||
| Q4 24 | 9.1% | 271.3% | ||
| Q3 24 | — | 72.2% | ||
| Q2 24 | -4.2% | 60.0% | ||
| Q1 24 | -77.3% | 71.2% |
资本支出强度APLSESNT
| Q4 25 | 0.1% | 2.4% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 2.1% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 0.2% | 1.5% |
现金转化率APLSESNT
| Q4 25 | — | 5.52× | ||
| Q3 25 | 0.50× | 1.31× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | 1.26× | ||
| Q4 24 | — | 5.13× | ||
| Q3 24 | — | 1.30× | ||
| Q2 24 | — | 0.93× | ||
| Q1 24 | — | 1.19× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ESNT
| Mortgage Insurance Segment | $192.4M | 62% |
| Other | $120.0M | 38% |
